37 results about "Aseptic loosening" patented technology

The invention discloses a method for preparing an antifriction wear-resistant F-DLC film on a titanium alloy surface. A plate hollow cathode HP-PECVD method is adopted. According to the plate hollow cathode HP-PECVD method, on the basis of a traditional PECVD method, a sample disk for carrying samples in an existing deposition system reaction chamber is changed into two parallel plates; a base body is placed between the two plates; negative bias voltage is applied to the space between the two plates to form a hollow cathode effect. The method specifically comprises the following steps of (1) pretreatment; (2) sputter cleaning; (3) deposition of a Si transition layer; and (4) deposition of the F-DLC film. The F-DLC film deposited on the titanium alloy surface through the method has the antifriction wear-resistant function, the tribology performance of titanium alloy in the vivo environment can be improved, and the problem that aseptic loosening complications caused by frictional wear of titanium alloy artificial joints is solved.

The present invention provides methods of preventing, treating, managing or ameliorating periodontal disease, Gorham-Stout disease, Wilson's disease, chronic otitis media, hypertrophic pulmonary osteoarthropathy or aseptic loosening of joint replacement (prostheses), or conditions associated therewith, utilizing antagonists of integrin alphavbeta3. The present invention encompasses the use of methods of preventing, treating, managing or ameliorating periodontal disease, Gorham-Stout disease, Wilson's disease, chronic otitis media, hypertrophic pulmonary osteoarthropathy, or aseptic loosening of joint replacement (prostheses), or conditions associated therewith, utilizing an integrin alphavbeta3 antagonist in combination with another therapy (e.g., another prophylactic or therapeutic agent). In particular, the present invention provides methods of preventing, treating, managing or ameliorating periodontal disease, Gorham-Stout disease, Wilson's disease, chronic otitis media, hypertrophic pulmonary osteoarthropathy or aseptic loosening of joint replacement (prostheses), or conditions associated therewith, comprising administering to a subject in need thereof at least one antagonist of integrin alphavbeta3 and at least one other therapy. The present invention encompasses compositions and articles of manufacture for use in preventing, treating, managing or ameliorating periodontal disease, or aseptic loosening of joint replacement (prostheses), Gorham-Stout disease, Wilson's disease, chronic otitis media, hypertrophic pulmonary osteoarthropathy or conditions associated therewith.

An animal intraosseous foreign body particle releasing device comprises an outer cylinder with one end open and the middle provided with a cavity communicated with an opening. The cavity is provided with inducing particles formed by at least one component of an artificial joint. The wall of the outer cylinder is provided with a plurality of release holes communicated with the cavity with the diameter less than the induced particles. The opening of the outer cylinder is sealed through a sealing member. The device can be used for preparation and basic research of a prosthesis aseptic loosening animal model and has the advantages of rapidness, stability and high repeatability.

The invention relates to the use of gene therapy in the treatment of aseptic loosening of orthopaedic prostheses and discloses methods of refixing such prostheses without open revision surgery. In particular, it provides adenoviral vectors and prodrugs for simultaneous, separate or sequential use in the destruction of interface tissue allowing subsequent recementing of loose prostheses in a minimally invasive manner.

The invention provides a prosthesis structure comprising a prosthesis main body and further comprising a protective coating applied to the outer surface of the prosthesis main body. The prosthesis structure comprises the prosthesis and the protective coating covering the prosthesis main body; the protective coating is applied to the outer surface of the prosthesis main body, so that the protective coating can cover the outer surface of the prosthesis main body made of Ti6Al4V alloy, the phenomenon of aseptic loosening of the prosthesis caused by Al and V ion release is avoided, the service life of the prosthesis is prolonged, damage to human bodies caused by Al ions and V ions can be prevented and the safety and reliability of using the prosthesis are improved.

The invention discloses a preparation process of a soft-soft contact-type bionic joint, and belongs to a preparation process of a bionic material. The preparation process comprises the following steps: 1) manufacturing an artificial knee femoral condyle, an artificial knee tibial liner, an artificial hip joint femoral head and an artificial hip joint acetabulum from medical polyethylene; 2) crosslinking the surface of a test sample with a PAMPS-PDMAAm composite hydrogel bionic cartilage material; 3) again crosslinking the test sample obtained in the step 2 with a PVA/HA-PAA composite hydrogel bionic cartilage material; and 4) again crosslinking the test sample obtained in the step 3 with a PVA hydrogel bionic cartilage material to finally obtain the soft-soft contact-type bionic joint. The bionic joint has a relatively low elastic modulus, high deformability, and excellent lubrication and wear resistance, can effectively reduce the impact, absorb the oscillation and reduce the impact and the wear during joint movement, and solves the problems of wear and aseptic loosening of an artificial joint.

The invention provides a preparation for diagnosing early-stage artificial hip joint aseptic loosening. The preparation comprises a human sandwich ELISA kit used as a preparation for diagnosing plasma interleukin 1gamma level, can also comprises a human rapid ELISA kit used as a preparation for detecting osteoprotegerin, and a Milliplex human single composite ELISA kit used as a preparation for detecting nucleus factor kappa-B acceptor activation factor ligand, or comprises any one of the three kits mentioned above. By detecting the levels of corresponding biological markers, artificial hip joint aseptic loosening can be effectively diagnosed in the early stage.

The invention discloses an artificial joint with a self-repairing textured composite film structure and a preparation method. The artificial joint comprises a radiation cross-linked ultra-high molecular weight polyethylene joint cup and a zirconia ceramic joint head, a circular hole micro-texture is processed on the inner surface of the joint cup, a capillary texture is processed on the surface of the joint head, and a layer of self-repairing textured composite film is grafted on the inner surface of the joint cup in friction with the joint head. The texturing adopted by the invention can improve the storage performance and the self-lubricating performance of the lubricating liquid to a great extent, and meanwhile, the self-repairing textured composite film can also enhance the adhesive force on the surface of the joint cup and is firm in combination; and the artificial joint is good in wear resistance and has the functions of self-repairing and sterile loosening prevention, and the service life of the artificial joint is prolonged.

The invention discloses an application of rhoifolin in preparation of a drug for preventing and treating osteolytic diseases. In-vitro experiments show that the rhoifolin can significantly inhibit theosteoclast formation and bone absorption induced by RANKL and also inhibit the expression of osteoclast-related genes. Western blotting experiments show that the rhoifolin can inhibit NF-[kappa]B andMAPK signaling pathways and two transcription factors of NFATc1 and c-fos; further studies show that the rhoifolin can inhibit P65 from entering nucleus and the activity of NFATc1 and NF-[kappa]B cells. In-vivo experiments show that the rhoifolin can reduce the number of TRAP-positive osteoclasts and bone destruction of skull in a titanium particle-induced skull model. Therefore, the rhoifolin can improve osteolysis induced by osteoclasts, and can become a potential drug for treatment of joint prosthesis loosening, and provides a new treatment option for aseptic loosening of prosthesis.

A joint fluid drainage system provides a solution to the aseptic loosening problem resulting from the utilization of total joint prostheses, lowering the pressure inside the joint capsule and draining the joint fluid comprising particles. The system includes a canal outlet starting from the articulation surface. This high pressure joint fluid with particles causing the loosening is drained from the capsule to the outside of the bone through a drainage path starting from this canal outlet, continuing in the prosthesis and the bone, and opening to the outer surface of the bone. The system also includes a silicone tube mounted to the canal outlet of the prosthesis by using the canal disposed in the bone. The tube is placed inside the fatty porous tissue located between the muscle groups outside the bone and the joint fluid is discharged into this area through this canal system by drainage.

The invention provides a femoral stem prosthesis which is internally provided with a cavity, one end of the femoral stem prosthesis is provided with a communication hole communicated with the cavity,a porous structure is embedded in the outer side wall of the femoral stem prosthesis, and holes in the porous structure are communicated with the cavity. After the femoral stem prosthesis is insertedinto a femoral medullary cavity, blood and nutrient substances can enter the femoral stem prosthesis from the communicated holes and are exchanged with external human sclerotin through the porous structure so that circulation of blood and nutrient substances is realized, local tissue necrosis is avoided, bone ingrowth is facilitated, osteoporosis or dissolution around the prosthesis is avoided, and postoperative aseptic loosening and ostealgia caused by postoperative aseptic loosening are eliminated, meanwhile, human bones can grow into holes in the porous structure, so that the implantation stability of the femoral stem prosthesis is greatly improved, in addition, due to the fact that hollowing and topological optimization are conducted on multiple positions of the femoral stem prosthesis, light weight is achieved, and the advantage of being light in weight is achieved.

The present invention relates generally to the field of implant related risk of revision, in particular implant related risk of revision not caused by an infection or metal on metal reaction. The present invention provides methods of diagnosing implant related risk of revision, use of kits for such diagnostic purposes and compositions for use in the treatment of implant related risk of revision, in particular implant related risk of revision not caused by an infection or metal on metal reaction.